Insmed (INSM)

• Market cap: $28.8B
• 1 day: -2.25%
• 5 days: -1.71%
• 1 month: -19.17%
• 3 months: -13.46%
• 6 months: -28.44%
• Year to date: -24.76%
• 1 year: 83.45%
• 5 years: 304.55%
• 10 years: 970.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Employees: 1,664